Difference between revisions of "User:Samuelrubinstein"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
(Updated bio) Tag: visualeditor |
||
| Line 1: | Line 1: | ||
[[File:Samuelrubinstein.jpg|thumb|Samuel Rubinstein, MD]] | [[File:Samuelrubinstein.jpg|thumb|Samuel Rubinstein, MD]] | ||
| − | Samuel Rubinstein MD is a | + | Samuel Rubinstein MD is a Clinical Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina-Chapel Hill Lineberger Comprehensive Cancer Center. His current research focuses on exploring outcomes and conducting clinical trials for patients with plasma cell dyscrasias including multiple myeloma and AL amyloidosis. He is also the site PI at UNC for the COVID-19 and Cancer Consortium (CCC-19). He is the HemOnc.org page editor for [[Light-chain (AL) amyloidosis]] and Smoldering Multiple Myeloma. |
Revision as of 15:17, 22 October 2020
Samuel Rubinstein MD is a Clinical Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina-Chapel Hill Lineberger Comprehensive Cancer Center. His current research focuses on exploring outcomes and conducting clinical trials for patients with plasma cell dyscrasias including multiple myeloma and AL amyloidosis. He is also the site PI at UNC for the COVID-19 and Cancer Consortium (CCC-19). He is the HemOnc.org page editor for Light-chain (AL) amyloidosis and Smoldering Multiple Myeloma.